May 8, 2013
San Diego, May 7, 2013 – The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) are pleased to announce the publication of the joint guideline on radiation therapy after prostatectomy for patients with and without evidence of prostate cancer recurrence.…
May 7, 2013
The Particulars: Metabolic syndrome has been shown in previous studies to be predictive of complications following liver and knee surgeries. The impact of metabolic syndrome on complications after genitourinary oncologic surgeries remains unknown.
Data Breakdown: For a study, investigators calculated the overall complication rates and identified predictors of complications among patients who underwent radical cystectomy, nephrectomy, and prostatectomy.…
May 6, 2013
SAN DIEGO — All of the current treatment strategies for castration-resistant prostate cancer (CRPC) exceed the generally accepted criteria for cost-effectiveness, according to an analysis reported here.
The least costly of the regimens exceeded the $100,000 threshold by about $60,000, and the most costly approached three times the threshold for willingness to pay per life-year saved.…
SAN DIEGO — Radical prostatectomy may offer the added benefit of urinary symptom reduction in prostate cancer patients who have concomitant lower urinary tract symptoms (LUTS), according to a study reported here.
The proportion of men who had clinically significant LUTS declined by almost 50% following radical prostatectomy, reported Vinay Prabhu, a medical student at New York University in New York City, and colleagues at the American Urological Association meeting.…
New guidelines on prostate cancer screening, issued today by the American Urological Association (AUA), are supportive of routine use of the prostate-specific antigen (PSA) test in healthy men, but only for a specified age group, and only after discussion between a man and his physician.…
December 10, 2012
Drug can now be used before treatment with chemotherapy
…
October 16, 2012
A study presented at the Anesthesiology 2012 annual meeting found that during the years 2000-2009, eye injuries during robotic-assisted radical prostatectomy (RARP) increased nearly 10-fold, from a .07 percent incidence rate to .42 percent.
Approved by the FDA in 2000, RARP has become increasingly used by surgeons to remove prostate cancer because it is minimally invasive, offers a shorter duration of hospital stay, and is associated with lower infection rates and decreased need for pain medications after surgery.…
October 4, 2012
University of North Carolina researchers have found that decision-making patterns appear to vary among patients with localized prostate cancer. Patient-only decision making (vs physician-only) was more likely among younger men and less likely for men with high cancer aggressiveness. The following were reported by study participants:
45% reported shared decision making.…
September 12, 2012
The U.S. Food and Drug Administration today approved the production and use of Choline C 11 Injection, a Positron Emission Tomography (PET) imaging agent used to help detect recurrent prostate cancer.
Choline C 11 Injection is administered intravenously to produce an image that helps to locate specific body sites for follow-up tissue sampling and testing in men with recurrent prostate cancer.…
August 31, 2012
The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.
Approved for prostate cancer patients previously treated with docetaxel, another anti-cancer treatment, Xtandi was reviewed under the FDA’s priority review program.…
